MicroStrategy has acquired 21,550 BTC for ~$2.1 billion at ~$98,783 per #bitcoin and has achieved BTC Yield of 43.2% QTD and 68.7% YTD. As of 12/8/2024, we hodl 423,650 $BTC acquired for ~$25.6 billion at ~$60,324 per bitcoin. $MSTR https://t.co/8r7bFqMFof
MicroStrategy has acquired 27,200 BTC for ~$2.03 billion at ~$74,463 per #bitcoin and has achieved BTC Yield of 7.3% QTD and 26.4% YTD. As of 11/10/2024, we hodl 279,420 $BTC acquired for ~$11.9 billion at ~$42,692 per bitcoin. $MSTR https://t.co/uCt8nNUVqd
Today, the Portage team had the chance to ring the @Nasdaq opening bell at Times Square in New York City! What a great way to celebrate our Nasdaq listing under $PRTG and our work in #ImmunoOncology, including progress on our #iNKT programs, in 2021.
I would encourage anyone who is looking at investment in any #oncology and #cancer biotech or leading Pharmeceutical company to listen to the interview with Ian Walters at Portage Biotech. This #iNKT technology with combination is going to revolutionise cancer treatments!
$PRTG
Today marks the beginning of #BreastCancerAwarenessMonth. Portage, is working with the FDA under the fast track program to develop novel treatments for #BreastCancer using technology to create antigens. Learn more here: https://t.co/Dlj5H6BAvm
“10 products will complete Phase 2 readouts over the next 18 months and 1 to. 2 new cancer drugs in clinic per year” says Ian Walters $PRTG @PortageBiotech
Advance treatment to aid the ability to cure cancers are coming from new technologies just being tested in humans for the first time “invariant natural killer T cells” iNKT
They switch on the #cancer cells to allow antibodies to work.
@PortageBiotech are on the frontline! $PRTG
Research published in May in @MedCellPress demonstrated that activation of #iNKT cells limited accumulation of pathologic senescent cells & improved survival in mice. iNKT cells may offer a path forward for anti-senescence therapies. Read the paper here: https://t.co/T85Ihwbp4B
@FinanceFunky $prtg curing cancer completely under the radar. 37 out of 37 in the trial still alive 9.5 months on. Pretty much any cancer. Doesn't get any better than that! https://t.co/C4BRy2vVPH
We have partnered with The Ottawa Hospital and The Ontario Institute for Cancer Research to conduct a Phase 2 trial of INT230-6 in patients with early stage #BreastCancer.
Read more: https://t.co/5GPjYd612y
@OttawaHospital@OICR_news
$PRTG $PTGEF $PTGED $BNTNF Well done to all at $PRTG today. Great management team and core investors that have a knack of delivering. Greg Bailey https://t.co/PfU9XKltRA
$PRTG - @portagebiotech
The new company coming to the #USA#NASDAQ on the 25th February! The company has a full portfolio of “cures for cancer”
Game changing for #oncology!
Set to be a phenomenal #investing opportunity!
This will probably get a #FFWD RNS tomorrow.
LGP to exclusively supply #cannabis to wide-ranging quality of Life study. Aiming to be one of the worlds largest longitudinal studies. Being done in Australia potential to be extended internationally